Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.

The Cbl proteins (Cbl, Cbl-b, and Cbl-c) are a highly conserved family of RING finger ubiquitin ligases (E3s) that function as negative regulators of tyrosine kinases in a wide variety of signal transduction pathways. In this study, we identify a new Cbl-c interacting protein, Enigma (PDLIM7). This...

Full description

Bibliographic Details
Main Authors: Stephen C Kales, Marion M Nau, Anand S Merchant, Stanley Lipkowitz
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3900716?pdf=render
id doaj-6a03ab554f364d1982b7553d1cc0a240
record_format Article
spelling doaj-6a03ab554f364d1982b7553d1cc0a2402020-11-25T00:18:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8711610.1371/journal.pone.0087116Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.Stephen C KalesMarion M NauAnand S MerchantStanley LipkowitzThe Cbl proteins (Cbl, Cbl-b, and Cbl-c) are a highly conserved family of RING finger ubiquitin ligases (E3s) that function as negative regulators of tyrosine kinases in a wide variety of signal transduction pathways. In this study, we identify a new Cbl-c interacting protein, Enigma (PDLIM7). This interaction is specific to Cbl-c as Enigma fails to bind either of its closely related homologues, Cbl and Cbl-b. The binding between Enigma and Cbl-c is mediated through the LIM domains of Enigma as removal of all three LIM domains abrogates this interaction, while only LIM1 is sufficient for binding. Here we show that Cbl-c binds wild-type and MEN2A isoforms of the receptor tyrosine kinase, RET, and that Cbl-c enhances ubiquitination and degradation of activated RET. Enigma blocks Cbl-c-mediated RETMEN2A ubiquitination and degradation. Cbl-c decreased downstream ERK activation by RETMEN2A and co-expression of Enigma blocked the Cbl-c-mediated decrease in ERK activation. Enigma showed no detectable effect on Cbl-c-mediated ubiquitination of activated EGFR suggesting that this effect is specific to RET. Through mapping studies, we show that Cbl-c and Enigma bind RETMEN2A at different residues. However, binding of Enigma to RETMENA prevents Cbl-c recruitment to RETMEN2A. Consistent with these biochemical data, exploratory analyses of breast cancer patients with high expression of RET suggest that high expression of Cbl-c correlates with a good outcome, and high expression of Enigma correlates with a poor outcome. Together, these data demonstrate that Cbl-c can ubiquitinate and downregulate RETMEN2A and implicate Enigma as a positive regulator of RETMEN2A through blocking of Cbl-mediated ubiquitination and degradation.http://europepmc.org/articles/PMC3900716?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Stephen C Kales
Marion M Nau
Anand S Merchant
Stanley Lipkowitz
spellingShingle Stephen C Kales
Marion M Nau
Anand S Merchant
Stanley Lipkowitz
Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
PLoS ONE
author_facet Stephen C Kales
Marion M Nau
Anand S Merchant
Stanley Lipkowitz
author_sort Stephen C Kales
title Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
title_short Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
title_full Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
title_fullStr Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
title_full_unstemmed Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
title_sort enigma prevents cbl-c-mediated ubiquitination and degradation of retmen2a.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description The Cbl proteins (Cbl, Cbl-b, and Cbl-c) are a highly conserved family of RING finger ubiquitin ligases (E3s) that function as negative regulators of tyrosine kinases in a wide variety of signal transduction pathways. In this study, we identify a new Cbl-c interacting protein, Enigma (PDLIM7). This interaction is specific to Cbl-c as Enigma fails to bind either of its closely related homologues, Cbl and Cbl-b. The binding between Enigma and Cbl-c is mediated through the LIM domains of Enigma as removal of all three LIM domains abrogates this interaction, while only LIM1 is sufficient for binding. Here we show that Cbl-c binds wild-type and MEN2A isoforms of the receptor tyrosine kinase, RET, and that Cbl-c enhances ubiquitination and degradation of activated RET. Enigma blocks Cbl-c-mediated RETMEN2A ubiquitination and degradation. Cbl-c decreased downstream ERK activation by RETMEN2A and co-expression of Enigma blocked the Cbl-c-mediated decrease in ERK activation. Enigma showed no detectable effect on Cbl-c-mediated ubiquitination of activated EGFR suggesting that this effect is specific to RET. Through mapping studies, we show that Cbl-c and Enigma bind RETMEN2A at different residues. However, binding of Enigma to RETMENA prevents Cbl-c recruitment to RETMEN2A. Consistent with these biochemical data, exploratory analyses of breast cancer patients with high expression of RET suggest that high expression of Cbl-c correlates with a good outcome, and high expression of Enigma correlates with a poor outcome. Together, these data demonstrate that Cbl-c can ubiquitinate and downregulate RETMEN2A and implicate Enigma as a positive regulator of RETMEN2A through blocking of Cbl-mediated ubiquitination and degradation.
url http://europepmc.org/articles/PMC3900716?pdf=render
work_keys_str_mv AT stephenckales enigmapreventscblcmediatedubiquitinationanddegradationofretmen2a
AT marionmnau enigmapreventscblcmediatedubiquitinationanddegradationofretmen2a
AT anandsmerchant enigmapreventscblcmediatedubiquitinationanddegradationofretmen2a
AT stanleylipkowitz enigmapreventscblcmediatedubiquitinationanddegradationofretmen2a
_version_ 1725377023048679424